24,977 Shares in DaVita Inc. (NYSE:DVA) Acquired by Atom Investors LP

Atom Investors LP bought a new position in DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 24,977 shares of the company’s stock, valued at approximately $4,094,000.

Several other institutional investors and hedge funds also recently made changes to their positions in DVA. Harvard Management Co. Inc. bought a new position in DaVita in the second quarter valued at approximately $55,115,000. FMR LLC boosted its stake in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA boosted its stake in DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after purchasing an additional 108,446 shares during the period. Point72 Asset Management L.P. bought a new position in DaVita during the 2nd quarter worth about $9,615,000. Finally, KBC Group NV grew its holdings in shares of DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after buying an additional 67,250 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the subject of several recent research reports. Bank of America increased their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Barclays increased their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, UBS Group boosted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $161.80.

DaVita Stock Performance

Shares of DVA stock opened at $166.17 on Monday. DaVita Inc. has a 52 week low of $99.18 and a 52 week high of $169.51. The company has a market capitalization of $13.63 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 0.94 and a beta of 0.89. The company has a 50-day simple moving average of $158.57 and a 200 day simple moving average of $149.39. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter last year, the business posted $2.85 EPS. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, sell-side analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is currently owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.